Illumina, Inc.

California
Pharmaceuticals Biotechnology and Life Sciences

Corporate Bias Rating

Expand Summary

Risk Level:

Rating - Danger
High Risk

Summary:

Illumina scored a 90 on the 2023 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. By complying with Human Rights Campaign’s controversial demands, Illumina increases the risk of dividing employees, alienating customers and harming shareholders. The company covers transgender-related medical costs for its employees and their children and provides specific sexual orientation and gender identity-based benefits. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, marketing, and philanthropic support. Illumina forces employees to undergo multiple ideological trainings and uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. Its CEO signed the CEO Action for Diversity & Inclusion pledge, which includes a commitment to promote DEI through bias education training in the workplace. Illumina sponsored an LGBTQ Pride event in San Francisco and pledged to match donations to the ACLU, Public Allies, and the Equal Justice Initiative. For these reasons, Illumina receives a High Risk rating.

Generate Reports
Clear
Toast